Keywords: درمان اندروژن محرومیت; Castration-resistant prostate cancer; Locally advanced prostate cancer; Enzalutamide; Apalutamide; Androgen deprivation therapy;
مقالات ISI درمان اندروژن محرومیت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Chemiluminescence; LHRH agonist treatment; Mass spectrometry; Testosterone;
Keywords: درمان اندروژن محرومیت; A.F; Alexander Falk; ADT; Androgen Deprivation Therapy; AMSTAR; Assessing the Methodological Quality of Systematic Reviews; BED; Biological Effective Dose; b-PFS; Biochemical Progression-Free Survival; BT; Brachytherapy; CI; Confidence Interval; CONSORT;
Keywords: درمان اندروژن محرومیت; Radical prostatectomy; Prostate cancer; Salvage radiotherapy; Androgen deprivation therapy;
Keywords: درمان اندروژن محرومیت; Luteinizing hormone-releasing hormone analogs; Prostate cancer; Androgen deprivation therapy; Cognitive function; Análogos de la hormona liberadora de la hormona luteinizante; Cáncer de próstata; Supresión androgénica; Función cognitiva;
Keywords: درمان اندروژن محرومیت; Prostate cancer recurrence; Androgen deprivation therapy (ADT); Choline-PET/CT; PSMA-PET/CT; Robotic salvage lymph node dissection; Complete biochemical response (cBCR); ADT; androgen deprivation therapy; BCR; biochemical recurrence; cBCR; complete bioche
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Biochemical failure; Postprostatectomy; Prostate bed; Prostate cancer; Prostatectomy; Radiotherapy; Salvage; Whole pelvis;
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Choice of therapy; Lymph node metastasis; Prostatectomy; Radiation therapy;
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Genomics; Neuroendocrine; Gleason score; Prostate cancer; Prostate-specific antigen; Small-cell cancer;
Keywords: درمان اندروژن محرومیت; Insulin; C-peptide; IGF-1; Body composition; 1-RM; 1 Repetition Maximum; ADT; Androgen Deprivation Therapy; AUC; Area Under the Curve; BMI; Body Mass Index; CRP; C-reactive Protein; CVD; Cardiovascular Disease; DBP; Diastolic Blood Pressure; FFM; Fat Free
Keywords: درمان اندروژن محرومیت; androgen antagonists; dementia; prostatic neoplasms; Alzheimer disease; cognition; ADT; androgen deprivation therapy; ICCTF; International Cognition and Cancer Task Force;
Keywords: درمان اندروژن محرومیت; Metastatic prostate cancer; Locally advanced prostate cancer; Hormone-naïve; Docetaxel; Abiraterone; Androgen deprivation therapy;
Keywords: درمان اندروژن محرومیت; Castrate-resistant prostate cancer; CRPC; Androgen deprivation therapy; ADT; LHRH; Immune therapy; Skeletal-related event (SRE);
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Castration-resistant prostate cancer; Growth factor receptor bound protein 10; Patient-derived xenografts;
Keywords: درمان اندروژن محرومیت; 6MWT; 6-Minute Walk Test; AACE; American Association of Clinical Endocrinologists; ACE; American College of Endocrinology; ADT; androgen deprivation therapy; BMI; body mass index; BRS; baroreflex sensitivity; CAC; coronary artery calcium; CAD; coronary ar
Keywords: درمان اندروژن محرومیت; prostatic neoplasms; prostate-specific antigen; brachytherapy; androgen antagonists; disease-free survival; ADT; androgen deprivation therapy; bDFS; biochemical disease-free survival; BF; biochemical failure; EBRT; external beam radiotherapy; LDR-BT; low
Keywords: درمان اندروژن محرومیت; Urolithins; Prostate cancer; Interactions; Ellagitannins gut metabolites; ADT; androgen deprivation therapy; AR; androgen receptor; bic; bicalutamide; CI; combination index; DHT; dihydrotestosterone; GnRH; gonadotropin-releasing hormone; PSA; prostate spe
Keywords: درمان اندروژن محرومیت; prostatic neoplasms; neoplasm recurrence; local; ultrasound; high-intensity focused; transrectal; postoperative complications; salvage therapy; ADT; androgen deprivation therapy; AE; adverse event; CaP; prostate cancer; EBRT; external beam radiation thera
Keywords: درمان اندروژن محرومیت; prostatic neoplasms; prostatectomy; high-intensity focused ultrasound ablation; cryotherapy; robotic surgical procedures; ADT; androgen deprivation therapy; BCR; biochemical recurrence; EBRT; external beam radiotherapy; HIFU; high intensity focused ultras
Keywords: درمان اندروژن محرومیت; prostatic neoplasms; androgen antagonists; non-alcoholic fatty liver disease; Medicare; SEER program; ADT; androgen deprivation therapy; AJCC; American Joint Committee on Cancer; NAFLD; nonalcoholic fatty liver disease; NASH; nonalcoholic steatohepatitis;
Keywords: درمان اندروژن محرومیت; prostatic neoplasms; castration-resistant; subcutaneous fat; prognosis; tomography; x-ray computed; mortality; ADT; androgen deprivation therapy; ARAT; androgen receptor axis targeted; BMI; body mass index; CCI; Charlson Comorbidity Index; CRPC; castratio
Keywords: درمان اندروژن محرومیت; ADT; androgen deprivation therapy; AE; adverse event; CRPC; castration-resistant prostate cancer; LHRH; luteinizing hormone-releasing hormone; mCRPC; metastatic CRPC; MFS; metastase-free survival; nmCRPC; non-metastatic CRPC; PFS; progression-free surviva
Keywords: درمان اندروژن محرومیت; prostatic neoplasms; castration-resistant; surveys and questionnaires; case reports; practice patterns; physicians; ADT; androgen deprivation therapy; CME; continuing medical education; CT; computerized tomography; LHRH; luteinizing hormone-releasing horm
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; ARAMIS; ARASENS; Darolutamide; Nonsteroidal; ODM-201;
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Castration-resistant prostate cancer (CRPC); Overall survival; Progression-free survival; Serum testosterone;
Keywords: درمان اندروژن محرومیت; PC; prostate cancer; mPC; metastatic prostate cancer; ADT; androgen deprivation therapy; CRPC; castration resistant prostate cancer; mCRPC; metastatic CRPC; SNP; single nucleotide polymorphism; CNV; copy number variation; AR; androgen receptor; CTC; circu
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Advanced prostate cancer; Time to progression; Predictive factor;
Keywords: درمان اندروژن محرومیت; Salivary duct carcinoma; Androgen deprivation therapy; Proton beam therapy; Androgen receptor; Salivary gland carcinoma;
Keywords: درمان اندروژن محرومیت; Low-dose-rate; Androgen deprivation therapy; Biochemical control; Intermediate risk; Prostate cancer; Brachytherapy;
Keywords: درمان اندروژن محرومیت; Castration-resistant prostate cancer; Prostate cancer; Androgen receptor; Androgen synthesis inhibitor; Androgen deprivation therapy; Novel androgen receptor antagonist; Abiraterone; Enzalutamide;
Keywords: درمان اندروژن محرومیت; Prostate cancer; Androgen deprivation therapy; Salvage radiation therapy; National Cancer Database; Practice patterns;
Keywords: درمان اندروژن محرومیت; Prostate cancer; Androgen deprivation therapy; Gonadotropin-releasing hormone; Orchiectomy; Cardiovascular risk; Prostate Cancer Database Sweden (PCBaSe);
Keywords: درمان اندروژن محرومیت; exercise; cancer related fatigue; prostate cancer; androgen deprivation therapy; meta-analysis;
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Depression; Prostate cancer; Behavioral symptoms; Hormone therapy;
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Cryotherapy; Radiation therapy; Radical prostatectomy; Variation in care;
Keywords: درمان اندروژن محرومیت; prostatic neoplasms; immunotherapy; ADT; androgen deprivation therapy; APC; antigen presenting cell; CRPC; castration resistant prostate cancer; GM-CSF; granulocyte-macrophage colony-stimulating factor; mCRPC; metastatic castration resistant prostate canc
Keywords: درمان اندروژن محرومیت; prostatic neoplasms; neoplasm staging; practice guidelines as topic; guideline adherence; ADT; androgen deprivation therapy; APC; advanced prostate cancer; CRPC; castration resistant prostate cancer; EMR; electronic medical record; IUOGP; integrated urolo
Keywords: درمان اندروژن محرومیت; ADT; androgen deprivation therapy; AR; androgen receptor; ASO; antisense oligonucleotide; CARN; castration-resistant Nkx3.1 expressing cells; CK; cytokeratin; CRPC; castration-resistant prostate cancer; DMBA; 7,12-dimethylbenz[a]anthracene; ECM; extracell
Keywords: درمان اندروژن محرومیت; Androgen; Androgen receptor; Androgen deprivation therapy; Castration resistant prostate cancer;
Keywords: درمان اندروژن محرومیت; Prostate cancer; Oncology; Cognitive functioning; Neurobehavioral functioning; Androgen deprivation therapy; Attributions; Quality of life;
Keywords: درمان اندروژن محرومیت; Prostate cancer survival; Androgen deprivation therapy;
Keywords: درمان اندروژن محرومیت; ADT; androgen deprivation therapy; AUA; American Urological Association; CaPSURE; Cancer of the Prostate Strategic Urologic Research Endeavor; cT; clinical tumor stage; EAU; European Association of Urology; ICD-O3; International Classification of Diseases
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Carcinoid; Drug resistance; Large cell neuroendocrine carcinoma; Neuroendocrine prostate cancer; Small cell carcinoma;
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Antiandrogen monotherapy; Castration; Deferred treatment; Prostate cancer;
Keywords: درمان اندروژن محرومیت; Pharmacogenomics; Prostate cancer; Androgen deprivation therapy; Chemotherapy; Steroid;
Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-
Keywords: درمان اندروژن محرومیت; Androgen deprivation therapy; Prostate cancer; Prostatectomy; Quality of life;
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results
Keywords: درمان اندروژن محرومیت; prostatic neoplasms; prostate-specific antigen; MDV 3100; bone density; drug related side effects and adverse reactions; ADT; androgen deprivation therapy; AE; adverse event; bALP; bone alkaline phosphate; BMD; bone mineral density; CR; complete response;
Additive effect of simultaneous continuous administration of degarelix and TAK-448 on LH suppression in a castrated rat model
Keywords: درمان اندروژن محرومیت; Degarelix (PubChem CID: 16136245); TAK-448 (PubChem CID: 46700761); Prostate cancer; Androgen deprivation therapy; Testosterone; Gonadotropin-releasing hormone antagonist; Kisspeptin analog; Drug combination;
Función cognitiva en pacientes tratados con supresión androgénica: estudio prospectivo y multicéntrico
Keywords: درمان اندروژن محرومیت; Análogos de la hormona liberadora de la hormona luteinizante; Cáncer de próstata; Supresión androgénica; Función cognitiva; Luteinizing hormone-releasing hormone analogues; Prostate cancer; Androgen deprivation therapy; Cognitive function;
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options
Keywords: درمان اندروژن محرومیت; prostate; prostatic neoplasms; guideline; ADT; androgen deprivation therapy; DRE; digital rectal examination; EBRT; external beam radiotherapy; HIFU; high intensity focused ultrasound; MRI; magnetic resonance imaging; PIVOT; Prostate Cancer Intervention V